您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Atropine sulfate monohydrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Atropine sulfate monohydrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Atropine sulfate monohydrate图片
CAS NO:5908-99-6
规格:≥98%
包装与价格:
包装价格(元)
250mg电议
500mg电议
1g电议
2g电议
5g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)694.83
Formula2(C17H23NO3).H2O.H2SO4
CAS No.5908-99-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 139 mg/mL (200 mM)
Water: 139 mg/mL (200 mM)
Ethanol: 139 mg/mL (200 mM)
Other info

Chemical Name: (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;sulfuric acid, hydrate

InChi Key: PVGPXGKNDGTPTD-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H23NO3.H2O4S.H2O/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12;1-5(2,3)4;/h2-6,13-16,19H,7-11H2,1H3;(H2,1,2,3,4);1H2

SMILES Code: O=S(O)(O)=O.O=C(OC1CC(N2C)CCC2C1)C(C3=CC=CC=C3)CO.[H]O[H]

Synonyms

Atropine sulphate; Sulfatropinol; Tropintran; Atropette; Corbella; Atropine Sulfate; Atropine Sulfate hydrate

实验参考方法
In Vitro

In vitro activity: Atropine increases the release of the neurotransmitter dopamine into the superfusate in vitro at 100-500 mM and into the vitreous in vivo at 250 mg. Atropine induces spreading depression (SD) in the in vitro preparation. Atropine reduces the ERG b- and d-wave, leads to damped oscillations of RPE potentials, and reverses the ERG c-wave. Atropine suppresses myopia only at doses at which severe nonspecific side effects are observed in the retina.


Kinase Assay: Atropine increases the release of the neurotransmitter dopamine into the superfusate in vitro at 100-500 mM and into the vitreous in vivo at 250 mg. Atropine induces spreading depression (SD) in the in vitro preparation. Atropine reduces the ERG b- and d-wave, leads to damped oscillations of RPE potentials, and reverses the ERG c-wave. Atropine suppresses myopia only at doses at which severe nonspecific side effects are observed in the retina.

In VivoAtropine (1.0 mg/kg, i.p.), but not methylatropine (1.0 mg/kg, i.p.), prevents the enhancement of retention induced by both doses of the anticholinesterase when given immediately after training in mice. Atropine administration effectively prevents bradycardia and second-degree heart block but induces pulsus alternans and hypertension in dogs. Atropine has no effect on handling-induced acetylcholine output in the presence of 10 nM neostigmine, but causes greater and longer increases in the presence of 100 nM and 1000 nM neostigmine in rats. Atropine not only blocks the rapid eye movement (REM) sleep increases induced by CGS but it also tends to decrease REM sleep compared to atropine preceding saline in rats. Atropine decreases the time to exhaustion by 67% in intact rats and by 96.2% in adrenodemedullated (ADM) and also reduces the exercise-induced pituitary prolactin (PRL) release in both intact (50%) and ADM rats (90%).
Animal modelMice
Formulation & Dosage1.0 mg/kg, i.p.
References

Vis Neurosci. 2000 Mar-Apr;17(2):165-76; Neurosci Lett. 2003 Jul 17;345(2):97-100.